Clinical Trial Update: A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy [Phase 2]

View source ↗

Summary

Phase II clinical trial investigating rituximab, chidamide, zanubrutinib-induced and CHOP therapy for double expressor diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CHOP therapy
• Chidamide (chidamide)
• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Double Express Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN